Signant SmartSignals® RTSM: Randomization And Cohort Management, IP Inventory Management

Signant’s SmartSignals® RTSM solution played a pivotal role in assisting an innovative biopharmaceutical company in obtaining an FDA Orphan Drug designation for its cardiomyopathy medication.

The trial protocol necessitated an RTSM system capable of accommodating multiple cohorts, each with diverse drug combinations and visit schedules. Our setup team meticulously analyzed the protocol, devised intricate on-site titration, dispensation, and scheduling algorithms, and effectively communicated the system's design to the client.

Discover how Signant's SmartSignals RTSM solution facilitated the seamless transition of eligible patients from Phase II to Phase III, while also furnishing the client with real-time insights into patient dosing and inventory levels, thus ensuring timely and informed decision-making.